BioSpace News Archive

Insulet Corporation today announced plans to release its financial results for the first quarter of 2020 on May 7, 2020 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The lin

LFB Announces FDA Approval of SEVENFACT ® , a New Recombinant Coagulation Factor VIIa, for the Treatment of Adults and Adolescents with Hemophilia A or B with Inhibitors LES ULIS, France--( BUSINESS WIRE )-- LFB today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) 2061 for SEVENFACT®, a new recombinant coagulation Factor VIIa [coagulation factor VIIa (recombinant)-jncw], for the treatment and con

Getinge, the world market leader in advanced ventilators for intensive care units, is announcing yet another ramp-up in production capacity, to 26,000 ventilators in 2020. The increase equals a growth of 160% compared to 2019, when 10,000 ventilators were produced. The demand for advanced ventilators for the intensive care

Luminex is now able to provide SARS-CoV-2 diagnostic tests for both high-complexity, high-throughput reference labs and moderate complexity, sample-to-answer testing facilities

Immunomedics, Inc.(NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that its Board of Directors (Board) has appointed Harout Semerjian as President and Chief Executive Officer (CEO) and as a member of the Board, effective April 16, 2020.

Last Patient Enrolled in DISRUPT CAD III, the U.S. FDA IDE Study for IVL in Severely Calcified Coronary Arteries

Catalyst Biosciences, Inc. today announced that it has received guidance from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on a pivotal Phase 3 trial design for Marzeptacog alfa (activated) – MarzAA. The open-label trial will evaluate the effi

Oncology Pharma, Inc. (OTCPK: ONPH) and Kalos Therapeutics (“Kalos”) announced today that the companies amended the terms of their collaboration to explore treatment opportunities of the COVID-19 virus, for the benefit of the most vulnerable cancer patients with cardiovascular issues and/or a weakened immune system.

Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, provided a corporate update in response to the COVID-19 pandemic.

Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) dedicated to development OT-101, a TGF-β antisense drug candidate, announced today that Mateon has delivered the requisite testing results to Golden Mountain Partners (GMP) confirming the applicability and potential use of OT-101 for the treatment of COVID-19. OT-101 exhibited potent activity against both COVID-19 and SARS with a robust safety index of >500